新抗原标靶治疗市场 - 全球产业规模、份额、趋势、机会和预测，按目标疾病适应症、新抗原类型、免疫疗法类型、给药途径、地区和竞争进行细分，2020-2030 年预测

2024 年全球新抗原标靶治疗市场价值为 18.8 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2030 年的复合年增长率为 8.34%。新抗原标靶治疗是癌症治疗的一种尖端方法，利用免疫系统的力量来专门识别和攻击癌细胞。这些疗法旨在针对新抗原，新抗原是由于肿瘤 DNA 的突变而在癌细胞表面发现的独特蛋白质片段。例如，根据《印度医学研究杂誌》 2022 年 12 月发表的一项研究，预计 2022 年印度新增癌症病例数为 14,61,427 例。该报告强调了该国日益加重的癌症负担，强调需要提高意识，早期发现，并改进治疗策略，以应对不断上升的发病率。新抗原不同于正常、健康的细胞蛋白，使其成为免疫辨识和攻击的理想目标。新抗原治疗是高度个人化的。一旦识别出新抗原，患者的免疫系统就会接受训练，将这些特定的新抗原识别为外来入侵者。这通常涉及根据患者独特的新抗原特征创建客製化疫苗或过继性细胞疗法。新抗原疗法可以与另一种免疫疗法检查点抑制剂合併使用。检查点抑制剂释放了免疫系统的煞车，使其能够对癌细胞（包括新抗原所针对的癌细胞）产生更强的反应。

基因组定序技术的日益普及和经济实惠使得人们能够更准确、更快速地识别新抗原，从而促进个人化治疗的发展。 FDA 和 EMA 等监管机构已表现出支持新抗原疗法开发和批准的意愿，简化了这些治疗方法的上市途径。患者和医疗保健提供者越来越多地寻求专门针对癌细胞的精准治疗方法。新抗原疗法有望实现更有效、毒性更小的治疗。研究人员正在探索将新抗原疗法与其他治疗方式（如化疗和放射疗法）结合的协同作用，以增强治疗效果。人口老化使罹患癌症的风险更高。随着全球人口老化，对包括新抗原疗法在内的创新癌症治疗的需求预计将上升。

主要市场驱动因素

基因组检测的进展

主要市场挑战

相关新抗原的鑑定

主要市场趋势

免疫疗法占主导地位

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球新抗原标靶治疗市场的影响

第 5 章：顾客之声

第六章：全球新抗原标靶治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依目标疾病适应症（骨癌、大肠直肠癌、妇科癌症、非小细胞肺癌、肾细胞癌）
  • 依新抗原类型（现成新抗原、个人化新抗原）
  • 依给药途径（皮内、静脉、皮下）
  • 依免疫疗法类型划分（树突细胞疫苗、基于 DNA / RNA 的疫苗、基于蛋白质 / 肽的疫苗、基于 TIL 的疗法）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 7 章：亚太地区新抗原标靶治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 8 章：欧洲新抗原标靶治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 9 章：北美新抗原标靶治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 10 章：南美洲新抗原标靶治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲新抗原标靶治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 12 章：市场动态

• 驱动程式
• 挑战

第 13 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 14 章：全球新抗原标靶治疗市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章： 大环境分析

第 17 章：竞争格局

• BioNtech SE
• Gritstone Bio, Inc.
• Genocea Biosciences Inc
• Moderna Inc.
• Agenus Inc.
• Immatics NV
• Advaxis Inc.
• Precision Biologics
• Gilead Sciences, Inc.
• Cellular Biomedicine Group, Inc.
• Achillies Therapeutics Plc.
• Merck & Co, Inc.

第 18 章：策略建议

第19章调查会社について・免责事项

Global Neoantigen Targeted Therapies Market was valued at USD 1.88 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.34% through 2030. Neoantigen Targeted Therapies are a cutting-edge approach in cancer treatment that harnesses the power of the immune system to specifically recognize and attack cancer cells. These therapies are designed to target neoantigens, which are unique protein fragments found on the surface of cancer cells because of mutations in the tumor's DNA. For instance, according to a study published by the Indian Journal of Medical Research in December 2022, the estimated number of new cancer cases in India for 2022 was 14,61,427. The report highlights the growing cancer burden in the country, emphasizing the need for enhanced awareness, early detection, and improved treatment strategies to address the rising incidence. Neoantigens are distinct from normal, healthy cell proteins, making them ideal targets for immune recognition and attack. Neoantigen therapies are highly personalized. Once neoantigens are identified, the patient's immune system is trained to recognize these specific neoantigens as foreign invaders. This often involves creating a customized vaccine or adoptive cell therapy tailored to the patient's unique neoantigen profile. Neoantigen therapies can be used in combination with checkpoint inhibitors, another type of immunotherapy. Checkpoint inhibitors release the brakes on the immune system, allowing it to mount a stronger response against cancer cells, including those targeted by neoantigens.

The growing availability and affordability of genomic sequencing technologies have enabled the identification of neoantigens more accurately and quickly, facilitating the development of personalized therapies. Regulatory agencies like the FDA and EMA have shown willingness to support the development and approval of neoantigen therapies, streamlining the path to market for these treatments. Patients and healthcare providers are increasingly seeking precision therapies that specifically target cancer cells. Neoantigen therapies offer the potential for more effective and less toxic treatments. Researchers are exploring the synergistic effects of combining neoantigen therapies with other treatment modalities, such as chemotherapy and radiation therapy, to enhance treatment outcomes. The aging population is at higher risk of developing cancer. As the global population ages, the demand for innovative cancer treatments, including neoantigen therapies, is expected to rise.

Key Market Drivers

Advancements in Genomic Testing

Next-generation sequencing technologies have revolutionized the field of genomics. NGS allows for the rapid and cost-effective sequencing of large stretches of DNA. It has enabled the sequencing of entire genomes, transcriptomes, and epigenomes with unprecedented speed and affordability. For instance, a study published in PNAS in September 2022 reported that researchers developed an antibody-based therapy that successfully eliminated circulating tumor cells (CTCs) in breast cancer mouse models. This breakthrough highlights the potential of targeted immunotherapy in preventing cancer metastasis, offering hope for improved treatment strategies and better outcomes for breast cancer patients in the future. High-throughput sequencing platforms can simultaneously process numerous DNA or RNA samples, allowing for large-scale studies and population-scale genomic research. This capability has accelerated the discovery of genetic variants associated with diseases and traits. Traditional short-read sequencing methods have limitations in resolving complex genomic regions. Long-read sequencing technologies, like Pacific Biosciences (PacBio) and Oxford Nanopore, can generate much longer sequencing reads, aiding in the assembly of complete genomes and the identification of structural variations. Single-cell sequencing technologies enable the analysis of individual cells within a tissue or organism. This approach provides insights into cellular heterogeneity, cell types, and gene expression at a single-cell resolution, advancing our understanding of complex biological systems. Genomic sequencing has been instrumental in cancer research and precision oncology. It allows for the identification of driver mutations, assessment of tumor heterogeneity, and the development of targeted therapies tailored to a patient's genetic profile.

Key Market Challenges

Identification of Relevant Neoantigens

Tumors are often genetically heterogeneous, meaning they contain a mix of different cell types with various mutations. Identifying the specific neoantigens that are present across all tumor cells can be challenging. Neoantigen prediction relies on computational algorithms to predict potential neoantigens based on DNA sequencing data. These algorithms are continually improving, but false positives and false negatives are still common, leading to uncertainty in selecting the most relevant neoantigens. Predicted neoantigens must be experimentally validated to confirm their presentation on cancer cells and their immunogenicity. This validation process can be time-consuming and resource intensive. Each patient's tumor has a unique set of neoantigens, and these can vary greatly from one patient to another. Identifying relevant neoantigens requires a personalized approach for each patient, which can be logistically challenging. Some neoantigens may be present at very low frequencies within a tumor, making them difficult to detect and target effectively. Tumors can evolve over time, leading to changes in their neoantigen landscape. This requires ongoing monitoring and adaptation of neoantigen-targeted therapies. Cancer cells may develop mechanisms to evade the immune system, including downregulating the presentation of neoantigens. This immune evasion can hinder the effectiveness of neoantigen-targeted therapies.

Key Market Trends

Immunotherapy Dominance

Immunotherapy has gained prominence as a leading approach in cancer treatment. It harnesses the body's immune system to target and destroy cancer cells. Neoantigen-targeted therapies are a subset of immunotherapy that focuses on training the immune system to recognize and attack cancer-specific neoantigens. Immunotherapy, including neoantigen-targeted therapies, aligns with the principles of precision medicine. These therapies are tailored to the individual genetic and immunological profiles of each patient, aiming to maximize treatment efficacy while minimizing side effects. Neoantigen-targeted therapies often complement the use of checkpoint inhibitors, another class of immunotherapies. Checkpoint inhibitors release the brakes on the immune system, allowing it to attack cancer cells more effectively. Neoantigens can serve as specific targets for the immune system to recognize in combination with checkpoint inhibitors. Neoantigen-targeted therapies aim to enhance the immune system's response against cancer cells by targeting neoantigens, which are unique to the tumor. This can lead to a more focused and potent immune response compared to traditional treatments. Positive outcomes and clinical successes in immunotherapy trials, including neoantigen therapies, have fueled interest and investment in this field. Patients who have experienced durable responses are advocating for and raising awareness of these treatments. The pharmaceutical and biotechnology industries have invested heavily in the research and development of immunotherapies, including neoantigen-based approaches. This investment has led to a growing pipeline of potential therapies.

Key Market Players

• BioNtech SE
• Gritstone Bio, Inc.
• Genocea Biosciences Inc.
• Moderna Inc
• Agenus Inc.
• Immatics NV
• Advaxis Inc
• Precision Biologics
• Gilead Sciences, Inc.
• Cellular Biomedicine Group Inc.
• Achillies Therapeutics Plc.
• Merck & Co Inc

Report Scope:

In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neoantigen Targeted Therapies Market, By Target Disease Indication:

• Bone Cancer
• Colorectal Cancer
• Gynecological Cancer
• Non-Small Cell Lung Cancer
• Renal Cell Carcinoma

Neoantigen Targeted Therapies Market, By Neoantigens Type:

• Off-the-Shelf Neoantigens
• Personalized Neoantigens

Neoantigen Targeted Therapies Market, By Immunotherapy Type:

• Dendritic Cell Vaccines
• DNA / RNA-Based Vaccines
• Protein / Peptide-based Vaccines
• TIL-Based Therapies

Neoantigen Targeted Therapies Market, By Route of Administration:

• Intradermal
• Intravenous
• Subcutaneous

Neoantigen Targeted Therapies Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.

Available Customizations:

Global Neoantigen Targeted Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Neoantigen Targeted Therapies Market

5. Voice of Customer

6. Global Neoantigen Targeted Therapies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)
  • 6.2.2. By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)
  • 6.2.3. By Route of Administration (Intradermal, Intravenous, Subcutaneous)
  • 6.2.4. By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map

7. Asia Pacific Neoantigen Targeted Therapies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Target Disease Indication
  • 7.2.2. By Neoantigens Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Immunotherapy Type
  • 7.2.5. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Neoantigen Targeted Therapies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Target Disease Indication
      • 7.3.1.2.2. By Neoantigens Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Immunotherapy Type
  • 7.3.2. India Neoantigen Targeted Therapies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Target Disease Indication
      • 7.3.2.2.2. By Neoantigens Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Immunotherapy Type
  • 7.3.3. Australia Neoantigen Targeted Therapies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Target Disease Indication
      • 7.3.3.2.2. By Neoantigens Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Immunotherapy Type
  • 7.3.4. Japan Neoantigen Targeted Therapies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Target Disease Indication
      • 7.3.4.2.2. By Neoantigens Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Immunotherapy Type
  • 7.3.5. South Korea Neoantigen Targeted Therapies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Target Disease Indication
      • 7.3.5.2.2. By Neoantigens Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Immunotherapy Type

8. Europe Neoantigen Targeted Therapies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Target Disease Indication
  • 8.2.2. By Neoantigens Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Immunotherapy Type
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Neoantigen Targeted Therapies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Target Disease Indication
      • 8.3.1.2.2. By Neoantigens Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Immunotherapy Type
  • 8.3.2. Germany Neoantigen Targeted Therapies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Target Disease Indication
      • 8.3.2.2.2. By Neoantigens Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Immunotherapy Type
  • 8.3.3. Spain Neoantigen Targeted Therapies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Target Disease Indication
      • 8.3.3.2.2. By Neoantigens Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Immunotherapy Type
  • 8.3.4. Italy Neoantigen Targeted Therapies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Target Disease Indication
      • 8.3.4.2.2. By Neoantigens Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Immunotherapy Type
  • 8.3.5. United Kingdom Neoantigen Targeted Therapies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Target Disease Indication
      • 8.3.5.2.2. By Neoantigens Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Immunotherapy Type

9. North America Neoantigen Targeted Therapies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Target Disease Indication
  • 9.2.2. By Neoantigens Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Immunotherapy Type
  • 9.2.5. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Neoantigen Targeted Therapies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Target Disease Indication
      • 9.3.1.2.2. By Neoantigens Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Immunotherapy Type
  • 9.3.2. Mexico Neoantigen Targeted Therapies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Target Disease Indication
      • 9.3.2.2.2. By Neoantigens Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Immunotherapy Type
  • 9.3.3. Canada Neoantigen Targeted Therapies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Target Disease Indication
      • 9.3.3.2.2. By Neoantigens Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Immunotherapy Type

10. South America Neoantigen Targeted Therapies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Target Disease Indication
  • 10.2.2. By Neoantigens Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Immunotherapy Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neoantigen Targeted Therapies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Target Disease Indication
      • 10.3.1.2.2. By Neoantigens Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Immunotherapy Type
  • 10.3.2. Argentina Neoantigen Targeted Therapies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Target Disease Indication
      • 10.3.2.2.2. By Neoantigens Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Immunotherapy Type
  • 10.3.3. Colombia Neoantigen Targeted Therapies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Target Disease Indication
      • 10.3.3.2.2. By Neoantigens Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Immunotherapy Type

11. Middle East and Africa Neoantigen Targeted Therapies Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Target Disease Indication
  • 11.2.2. By Neoantigens Type
  • 11.2.3. By Route of Administration
  • 11.2.4. By Immunotherapy Type
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Neoantigen Targeted Therapies Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Target Disease Indication
      • 11.3.1.2.2. By Neoantigens Type
      • 11.3.1.2.3. By Route of Administration
      • 11.3.1.2.4. By Immunotherapy Type
  • 11.3.2. Saudi Arabia Neoantigen Targeted Therapies Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Target Disease Indication
      • 11.3.2.2.2. By Neoantigens Type
      • 11.3.2.2.3. By Route of Administration
      • 11.3.2.2.4. By Immunotherapy Type
  • 11.3.3. UAE Neoantigen Targeted Therapies Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Target Disease Indication
      • 11.3.3.2.2. By Neoantigens Type
      • 11.3.3.2.3. By Route of Administration
      • 11.3.3.2.4. By Immunotherapy Type

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Neoantigen Targeted Therapies Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. BioNtech SE
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (In case of listed companies)
  • 17.1.5. Recent Developments
• 17.2. Gritstone Bio, Inc.
• 17.3. Genocea Biosciences Inc
• 17.4. Moderna Inc.
• 17.5. Agenus Inc.
• 17.6. Immatics N.V.
• 17.7. Advaxis Inc.
• 17.8. Precision Biologics
• 17.9. Gilead Sciences, Inc.
• 17.10. Cellular Biomedicine Group, Inc.
• 17.11. Achillies Therapeutics Plc.
• 17.12. Merck & Co, Inc.

18. Strategic Recommendations

19. About Us & Disclaimer